Paul has worked for Pfizer since September 1997 as a process engineering scientist for Groton, CT Developmental Research and more recently for Pharmaceutical R&D in the Animal Health Division. Over the years he has managed fermentation, bioreaction, downstream processing teams and eventually took over responsibilities for managing the formulation and analytical chemistry labs for vaccine development.
Currently his research focus lies in vaccine adjuvant formulation and he has developed a comprehensive first-of-itýs-kind database that allows researchers to compare the numerous aspects of over hundreds of adjuvant formulations and immunomodulators. Paul has over 20 different patents pertaining to vaccines, processes, cryopreservation and immune modulation. His most notable achievement was the development of a tunable adjuvant system for vaccines that allows for the "tilting" of a Th1 or Th2 bias depending on the requirements of the application. Additionally, Paul is a recipient of the Pfizer Global Innovation Achievement Award and several other notable achievement awards over his years at Pfizer.
On his Fellowship assignment with GALVmed, Paul will be supporting vaccine development targeting numerous animal diseases. From his GHF experience, Paul hopes to learn more about the challenges of vaccine development in other parts of the world. He believes he will return from his assignment with more tolerance, additional skills and an understanding of developing world cultures.
GALVmed is a not-for-profit global alliance of public, private and government partners, protecting livestock and saving human life by making livestock vaccines, diagnostics and medicines accessible and affordable to the millions for whom livestock is a lifeline. With offices in the United Kingdom and Africa, GALVmed is funded by the Bill & Melinda Gates Foundation and the Department for International Development.